| Sign In to gain access to subscriptions and/or personal tools. |
Menstrual and hormonal alterations in juvenile systemic lupus erythematosusPaediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Gynecology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Paediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil clovis.silva{at}icr.usp.br Menstrual cycles of 30 patients with juvenile systemic lupus erythematosus (JSLE) were compared with 30 age-matched controls. The mean age of patients with JSLE and controls was similar (17.4 ± 3.2 vs 17.06 ± 2.08 years, P = 0.66). The mean menarche age was higher in JSLE than controls (13.13 ± 1.4 vs 11.56 ± 1.5 years, P = 0.0008). On the contrary, the mean maternal menarche age was similar in both groups (P = 0.62). Menstrual abnormalities and longer length cycles were more frequently observed in JSLE than controls (63% vs 10%, P = 0.0001; 23% vs 0%, P = 0.0105, respectively). The median of follicle stimulating hormone was significantly higher in patients with JSLE compared with controls (4.6 vs 3.4 IU/L, P = 0.0207), and the median of progesterone was lower (32.5 vs 70 ng/mL, P = 0.0033). The median of luteinizing hormone was lower in patients with JSLE with menstrual abnormalities versus normal cycles (2.9 vs 5.5 IU/L, P = 0.019) and both had a high percentage of decreased progesterone levels (63% vs 73%, P = 0.70). Our findings support the notion that menstrual disturbances are frequent and may be associated with pituitary dysfunction leading to a decreased progesterone production. We also reported that in spite of premature ovarian failure being a rare event in JSLE the follicular reserve seems to be low regardless of intravenous cyclophosphamide treatment.
Key Words: adolescent hormone juvenile systemic lupus erythematosus menarche menstrual abnormalities
Lupus, Vol. 18, No. 1,
38-43 (2009) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||